Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Furmonertinib vs Osimertinib in EGFR+ NSCLC with Brain Metastases
NCT06319950Phase 2Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Taizhou Hospital of Zhejiang Province. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06319950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319950.